|Jeffrey A. Lieberman|
|Residence||New York City|
|Institutions||American Psychiatric Association, Columbia University, New York State Psychiatric Institute, University of North Carolina School of Medicine, Mount Sinai School of Medicine, Albert Einstein College of Medicine, Zucker Hillside Hospital of Long Island Jewish Medical Center|
|Alma mater||George Washington University Medical School, Saint Vincent's Catholic Medical Center|
|Known for||Schizophrenia research, NIMH CATIE study|
|Notable awards||Lieber Prize for Schizophrenia Research from the National Association for Research in Schizophrenia and Affective Disorders; the Adolph Meyer Award from the American Psychiatric Association; the Research Award from the National Alliance on Mental Illness, and the Neuroscience Award from the International College of Neuropsychopharmacology|
Jeffrey Alan Lieberman (born 1948) is an American psychiatrist who specializes in schizophrenia and related psychoses and their associated neuroscience (biology) and drugs. He was principal investigator for CATIE, the largest and longest independent study ever funded by the United States National Institute of Mental Health to examine existing therapies for schizophrenia. He was past president of the American Psychiatric Association from May 2013 to May 2014.
Lieberman is the Lawrence E. Kolb Professor and chairman of psychiatry at the Columbia University College of Physicians and Surgeons and director of the New York State Psychiatric Institute. He also holds the Lieber Chair and directs the Lieber Center for Schizophrenia Research in the Department of Psychiatry at Columbia and serves as the psychiatrist in chief of NewYork-Presbyterian Hospital-Columbia University Medical Center.
Education and early career
Lieberman graduated from Miami University in 1970, and then received his medical degree from the George Washington School of Medicine in 1975. Following his postgraduate training in psychiatry at St. Vincent’s Hospital and Medical Center of New York Medical College, he was on the faculties of the Mount Sinai School of Medicine and Albert Einstein College of Medicine, and served as director of research at the Zucker Hillside Hospital of Long Island Jewish Medical Center.
Prior to moving to Columbia University, he was vice chairman for Research and Scientific Affairs in the UNC Department of Psychiatry and Director of the Mental Health and Neuroscience Clinical Research Center at the University of North Carolina at Chapel Hill School of Medicine.
Lieberman’s research has focused on the neurobiology, pharmacology and treatment of schizophrenia and related psychotic disorders. In this context, his work has advanced our understanding of the natural history and pathophysiology of schizophrenia and the pharmacology and clinical effectiveness of antipsychotic drugs.
Financial Conflict of Interest (FCOI)
As of June 2013, as disclosed in Annals of Internal Medicine, the British Journal of Psychiatry, and JAMA, Lieberman’s disclosure of financial conflict of interest is on file with the International Committee of Medical Journal Editors (ICMJE). ICMJE disclosure and review includes FCOI categories: research grants/industry ties, consulting and honorarium, participation in Data Safety Monitoring Boards (DSMB), provision of research meds or equipment, writing/royalties, administrative support, expert testimony, speakers bureaus, patents, stocks and stock options, travel.
A note on "competing interests" for contributors to hisEssentials of Schizophrenia (2011) stated that Lieberman received no direct financial compensation for his research, consulting and advisory board activities other than Intra-Cellular Therapies.
In 2006, Lieberman co-signed a letter to the editor of The Wall Street Journal with around thirty other doctors. In the letter, disclosed honoraria, consulting fees, research grant support from AstraZeneca, Bristol-Myers Squibb, Upjohn Pharmacia, Novartis, Eli Lilly, Janssen, Pfizer, Hoechst AG, and AstraZeneca. He also listed as corporate speakers bureaus AstraZeneca, Janssen, Eli Lilly, and Pfizer. Lieberman disclosed in 2007 in the journal Primary Psychiatry that he was a consultant to Eli Lilly and Pfizer. He was on the advisory boards of AstraZeneca, Eli Lilly, GlaxoSmithKline, Lundbeck, Organon, and Pfizer. He has a patent from Repligen Corporation. Lieberman received research support from Acadia, Bristol-Myers Squibb, GlaxoSmithKline, Janssen, Merck, Organon, and Pfizer. In 2009, Lieberman disclosed grants from Allon, Forest Laboratories, Merck, Pfizer, AstraZeneca, Bristol-Myers Squibb, Cephalon, GlaxoSmithKline, Janssen, Otsuka, Solvay, and Wyeth to the American College of Neuropsychopharmacology for their annual meeting in which he participated. In 2011, his disclosure at Medscape of relevant financial relationships says he served on the advisory board of Bioline, GlaxoSmithKline, Intra-Cellular Therapies, Eli Lilly, Pierre Fabre, and Psychogenics, and that he received research grants from Allon Therapeutics, GlaxoSmithKline, Ortho-McNeil-Janssen, Merck, Novartis, Pfizer, Sepracor, and Targacept. He also disclosed in 2013, as a member of the psychiatry editorial board at Medscape, that he received research grants from Allon, Novartis, Sepracor, and Targacept; and he served on the advisory boards at Bioline, Intra-Cellular Therapies, Pierre Fabre and Psychogenics. In additional disclosures at Medscape in 2013, he received research grants from Allon, GlaxoSmithKline, Eli Lilly, Merck, Novartis, Pfizer, Psychogenics, Hoffmann-La Roche, Sepracor, and Targacept, and he served on the advisory board of Alkermes, Bioline, Intra-Cellular Therapies, Pierre Fabre, and Psychogenics.
Lieberman served as principal investigator for Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) sponsored by the National Institute of Mental Health (NIMH). The investigators compared a, "first-generation antipsychotic, perphenazine, with several newer drugs in a double-blind study". "Probably the biggest surprise of all was that the older medication produced about as good an effect as the newer medications, three of them anyway, and did not produce neurological side effects at greater rates than any of the other drugs," Lieberman told The New York Times.
Writing in her blog at Scientific American, Judy Stone called Lieberman "self-promotional and condescending" in his guest blog. She also claimed that Lieberman was responsible for ethical breaches in the CAFE study, funded by AstraZeneca, which caused the death of Dan Markingson who was enrolled in that study by the University of Minnesota. He has also been accused of removing anti-psychotic drugs from patients and giving them psychogenic drugs in experiments and then, when discussed in the press, calling investigative journalist Robert Whitaker a “menace to society” on CBC radio.
Lieberman's work has been reported in more than 450 articles in the scientific literature and he has edited or co-edited eight books, including the textbook Psychiatry, currently in its second edition, Textbook of Schizophrenia, Comprehensive Care of Schizophrenia, Psychiatric Drugs and Ethics in Psychiatric Research: A Resource Manual on Human Subjects Protection. He also serves, or has served, as associate editor of the American Journal of Psychiatry, Biological Psychiatry, Neuropsychopharmacology, Acta Psychiatrica Scandinavica, Schizophrenia Research, NeuroImage, The International Journal of Neuropsychopharmacology, and Schizophrenia Bulletin.
Awards, honors, and memberships
Lieberman is a member of the National Academy of Sciences Institute of Medicine and a fellow of the American Association for the Advancement of Science (AAAS). He received the Lieber Prize for Schizophrenia Research from NARSAD, the Adolph Meyer Award from the American Psychiatric Association (APA), the Stanley R. Dean Award for Schizophrenia Research from the American College of Psychiatrists, the APA Research Award, the APA Kempf Award for Research in Psychobiology, the APA Gralnick Award for Schizophrenia Research, the Ziskind-Somerfeld Award of the Society of Biological Psychiatry, the Ernest Strecker Award of the University of Pennsylvania, the Lilly Neuroscience Award from the Collegium Internationale Neuro-Psychopharmacologicum for Clinical Research, the Scientific Research Award and the Exemplary Psychiatrist Award from the National Alliance on Mental Illness, the Ed Hornick Memorial Award of The New York Academy of Medicine, the Strecker Award of the Department of Psychiatry at the University of Pennsylvania. He is or has been a member of the advisory committee for Neuropharmacologic and Psychopharmacologic Drugs of the Food and Drug Administration, the Planning Board for the Surgeon General’s Report on Mental Health, the Committee on Research on Psychiatric Treatments of the APA, the APA Work Group for the Development of Schizophrenia Treatment Guidelines, the Brain Disorders and Clinical Neuroscience Review Committee, the National Advisory Mental Health Council of the NIMH, and currently chairs the APA Council of Research.
He resides with his husband and two adopted sons in New York City.
- "Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE)". National Institute of Mental Health. 2005 to 2008. Retrieved May 26, 2013. Check date values in:
- "Questions and Answers About the NIMH Clinical Antipsychotic Trials of Intervention Effectiveness Study (CATIE) — Phase 1 Results". National Institute of Mental Health, U.S. Department of Health and Human Services. September 2005. Retrieved May 28, 2013.
- "Jeffrey A. Lieberman". Columbia University. Retrieved May 26, 2013.
- "Jeffrey Lieberman, M.D.". Columbia University Department of Psychiatry. 2005 to 2008. Retrieved May 26, 2013. Check date values in:
- ICMJE FCOI Form
- Lieberman, Jeffrey A.; et al. (2011). Essentials of Schizophrenia. American Psychiatric Pub via Google Books. p. xiii. ISBN 1585624012.
- "2 letters Re: Dr. Nemeroff Failure to Disclose Conflicts of Interest_WSJ". Alliance for Human Research Protection. September 22, 2006. Retrieved May 27, 2013.
- Norman Sussman, MD (April 16, 2007). "In Session with Jeffrey A. Lieberman, MD: Tardive Dyskinesia". Primary Psychiatry. MBL Communications. pp. 35–38. Retrieved May 26, 2013.
- "2009 ACNP Annual Meeting Disclosures". American College of Neuropsychopharmacology. Retrieved May 27, 2013.
- Jeffrey A. Lieberman, MD (September 28, 2011). "Disclosures in: Psychiatric Diagnosis in the Lab: How Far Off Are We?". Medscape. WebMD. Retrieved May 27, 2013.
- "Jeffrey A. Lieberman, MD". WebMD. Retrieved May 26, 2013.
- Lieberman, Jeffrey A., MD (January 30, 2013). ""Disclosures" in: A Long Way From 'Insanity and Idiocy'". Medscape. WebMD. Retrieved May 27, 2013.
- Lieberman, Jeffrey A.; et al. (September 22, 2005). "Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia". The New England Journal of Medicine. Massachusetts Medical Society. 353 (12): 1209–1223. doi:10.1056/NEJMoa051688. PMID 16172203.
- Carey, Benedict (September 20, 2005). "Little Difference Found in Schizophrenia Drugs". The New York Times. Retrieved May 30, 2013.
- Stone, Judy (May 24, 2013). "Anti-Psychiatry Prejudice? A response to Dr. Lieberman". Scientific American. Retrieved May 30, 2013.
- "CAFE Comparison of Atypicals in First Episode of Psychosis: ClinicalTrials.gov Identifier NCT00034892 (completed)". U.S.National Institutes of Health. May 2, 2002 to March 2005. Retrieved May 30, 2013. Check date values in:
- "Prestigious Lieber Prize for Research Awarded to Jeffrey A. Lieberman, M.D". National Institute of Mental Health. October 12, 2006. Retrieved May 26, 2013.
- "Reception and Presentation of the 2011 NAMI Scientific Research Award". National Alliance on Mental Illness. Retrieved May 26, 2013.
- "Jeffrey A. Lieberman Receives Hornick Award; Delivers Lecture on Early Interventions for Schizophrenia". The New York Academy of Medicine. January 12, 2012. Retrieved May 26, 2013.
- "Previous Strecker Award Recipients". The Trustees of the University of Pennsylvania. Retrieved May 26, 2013.